

This material is an English translation of the press release announced on Jul. 13, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.

Jul. 13, 2023

Notification Regarding Concerning the Decision of Matters

Relating to Acquisition of Company's Own Shares

(Acquisition of company's own shares under the regulations of the articles of association
in accordance to paragraph 2, article 165 of the corporation law)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President and CEO: Kazuhide Nakatomi) hereby notices that it resolved matters relating to acquisition of company's own shares as follows under the regulations of Article 156 of the Corporations Laws as being changed to read and applied upon the regulations of Paragraph 3, Article 165 of the Corporation Law at the Meeting of the Board of Directors held today.

1. Reason to acquire company's own shares

To improve capital efficiency and to attempt more distribution of profit to shareholders, and to perform mobile capital policy corresponding to the change of managerial environment.

2. Content of matters concerning acquisition

(1) Class of targeted shares to acquire: Common shares of Hisamitsu

(2) Total number of shares acquirable: Two million shares (ceiling)

(Ratio to total number of issued shares [excluding company's own shares] 2.57%)

(3) Total amount of acquired value of share: 10 billion yen (ceiling)

(4) Period for acquisition: From July 14, 2023 to February 29, 2024

(5) Method of acquisition: Market purchase on the Tokyo Stock Exchange

(Reference:) Condition of company's own shares held as of May 31, 2023

Total number of issued shares (excluding company's own shares): 77,773,522 shares.

Number of company's own shares: 7,391,373 shares.